No Data
Director Yao Zhuangmin of Sirio Pharma (300791.SZ) has completed a shareholding of 0.1485 million shares.
Sirio Pharma (300791.SZ) issued an announcement that as of January 25, 2025, this shareholding plan has been ...
Sirio Pharma (300791.SZ): plans to launch a restricted stock incentive program of 1.8886 million shares.
On January 12, Glonghui announced that Sirio Pharma (300791.SZ) revealed its 2025 restricted stock incentive plan, proposing to grant a total of 1.8886 million shares of restricted stock to the incentive objects, which accounts for approximately 0.80% of the company's total share capital of 235.87288 million shares as of the announcement date. Among them, the initial grant of restricted stock is 1.511 million shares, accounting for about 0.64% of the company's total share capital of 235.87288 million shares as of the announcement date, and 80.01% of the total number of restricted stocks proposed for granting in this incentive plan; 0.3776 million shares are reserved.
Investors Don't See Light At End Of Sirio Pharma Co., Ltd.'s (SZSE:300791) Tunnel
Fangzheng Securities: The selection model for supermarkets is rapidly developing. Attention is drawn to the supply chain of high-quality leaders in the CSI SWS Food & Beverage index.
Currently, online traffic growth is slowing down, while offline channels are regaining some customer flow. Among these, the share of traditional key account large supermarkets is rapidly shrinking, whereas specialty selection model supermarkets are beginning to thrive.
Is It Time To Consider Buying Sirio Pharma Co., Ltd. (SZSE:300791)?
Returns On Capital At Sirio Pharma (SZSE:300791) Have Hit The Brakes
Take Care Before Diving Into The Deep End On Sirio Pharma Co., Ltd. (SZSE:300791)
